For women who have experienced complications during pregnancy, the cardiovascular consequences can extend far beyond delivery — and a new 15-year cohort analysis sharpens that picture considerably. Understanding which clinical signals best predict chronic hypertension after pregnancy has direct implications for how ob-gyns and primary care physicians prioritize postpartum monitoring and early intervention.
Drawing from the LIFECODES biobank, researchers followed 993 women enrolled between 2006 and 2008, tracking second-trimester and third-trimester serum levels of sFlt-1 and placental growth factor (PlGF) alongside long-term hypertension outcomes. Nearly 46% of participants developed stage 1 or stage 2 hypertension over the follow-up period — a striking prevalence. A prior diagnosis of gestational hypertension carried an adjusted hazard ratio of 3.50 (95% CI: 2.21–5.54), while a history of preeclampsia was associated with a hazard ratio of 2.17 (95% CI: 1.44–3.28). Notably, the sFlt-1/PlGF ratio — widely used to predict acute preeclampsia severity — showed no significant independent association with long-term hypertension risk. PlGF levels alone, however, were modestly but significantly higher in women who remained normotensive over follow-up.
This finding carries important nuance for clinicians who might assume that angiogenic biomarkers predictive of acute placental dysfunction would also forecast chronic vascular disease. They do not appear to, at least not independently. The clinical history — specifically, whether a woman had gestational hypertension or preeclampsia — remains the more powerful and accessible long-term risk signal. This aligns with existing cardiovascular literature linking hypertensive disorders of pregnancy to elevated lifetime risk of heart disease and stroke, but the magnitude of the gestational hypertension hazard ratio here (3.5-fold) is notably higher than preeclampsia's (2.2-fold), which inverts a common clinical intuition that preeclampsia is the more serious sentinel event. The retrospective design and single-biobank cohort limit generalizability, and residual confounding cannot be excluded. Still, the findings reinforce obstetric history as an underutilized cardiovascular risk stratification tool that warrants broader integration into routine primary care.